Drug Pipeline

ARX788 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
2
Recruiting
3
Top Sponsors
3
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-12 NCT06224673
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic…		 Recruitment opened
2026-06-12 NCT06224673
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic…		 date change Primary completion pushed: 2029-09-30 -> 2029-11-30
2026-06-12 NCT06224673
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic…		 date change Completion pushed: 2029-09-30 -> 2029-11-30
Active Studies by Phase
Phase 2
3
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT01042379 I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Breast Neoplasms Recruiting
NCT06224673 ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic… HER2 Low Breast Carcinoma Recruiting
NCT04829604 ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) HER2 Positive Metastatic Breast Cancer Active, Not Recruiting
Sponsors Running ARX788 Trials
QuantumLeap Healthcare Collaborative (1) Ambrx, Inc. (1) Laura Huppert, MD, BA (1)
Disease Areas
Breast Cancer (3) Triple-Negative Breast Cancer (2) HER2-Positive Breast Cancer (1) Sarcoma (1)
Get alerts when ARX788 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free